<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed outcomes of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or secondary <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (sAML) that were treated at our institution with a reduced intensity conditioning (RIC) regimen of 550-cGy total body irradiation and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> followed by related donor (RD) or unrelated donor (URD) transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-one consecutive patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or sAML received this RIC regimen and URD (n = 30) or RD (n = 21) stem cells </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> alone (RD) or with <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (URD) </plain></SENT>
<SENT sid="3" pm="."><plain>Median patient age was 44 years </plain></SENT>
<SENT sid="4" pm="."><plain>With a median follow-up of 3.7 years after transplantation in the 19 surviving patients (37%), Kaplan-Meier estimates of overall survival were 88%, 46%, 33%, and 11% for patients transplanted with sAML in remission, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation, or sAML refractory/untreated, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Kaplan-Meier estimates of relapse-free survival were 75%, 46%, 33%, and 11%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, the cumulative incidences of relapse and transplant-related mortality were 27% and 37%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, this is an effective RIC regimen for allogeneic transplantation that can be used as an alternative to other RIC or conventional conditioning regimens </plain></SENT>
</text></document>